The inflammatory chemokines CCL2 and CCL5 in breast cancer.

By G. Soria, A. Ben-Baruch. Cancer Letters, 2008

604 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/fc9b75ebf453158a0d4c3376a96c370866ac4f98

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Condeelis
2. Larry Norton
3. E. Roussos
4. Z. Granot
5. E. Henke
6. A. Patsialou
7. J. Pollard

In Oncology

1. J. Condeelis
2. Larry Norton
3. J. Slingerland
4. E. Roussos
5. Z. Granot
6. E. Henke
7. A. Patsialou
8. J. Pollard

Citations in the corpus

• Chemotaxis in cancer (2011, background): “Additionally, CCL2 and CCL5 are major attractants of monocyte precursor cells in tumours and, when accumulated, these cells play an important part in tumour non-responsiveness by suppressing antigen-specific T cell response”
• Tumor entrained neutrophils inhibit seeding in the premetastatic lung (2011, positive): “Several studies have shown that CCL2 has a protumorigenic effect and that high CCL2 serum levels in cancer patients are associated with advanced disease and a poor prognosis (Soria and Ben-Baruch, 2008).”
• Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention (2017, background): “CCL2 and CCL5 also mediate tumor-promoting cross-talk between cancer cells and the microenvironment.(127,129) Both chemo-”